The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2018 | Thoughts on the use of MRD in CLL
Daniel Catovsky
• 25 Oct 2018
Daniel Catovsky, MD, DSc, FRCP, FRCPath, FMedSci, of the Institute of Cancer Research, London, UK, gives us his thoughts on the use of measurable residual disease testing (MRD) in the field of chronic lymphocytic leukemia (CLL), from the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
